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A B S T R A C T
Objectives: Given a lack of universally-accepted standard-of-care treatment for patients with recurrent/meta-
static head and neck squamous cell carcinoma (R/M HNSCC), study objectives were to assess treatment utili-
zation and survival outcomes for R/M HNSCC in the real-world setting.
Materials and methods: A multi-site retrospective chart review was conducted in Europe (Germany, United
Kingdom, Italy, Spain), Asia Pacific (Australia, South Korea, Taiwan), and Latin/North America (Brazil and
Canada) to identify patients who initiated first-line systemic therapy for R/M HNSCC between January 2011 and
December 2013. Patients were followed through December 2015 to collect clinical characteristics, treatment and
survival data.
Results: Among 733 R/M HNSCC patients across 71 sites, median age was 60 years (inter-quartile range 54–67),
84% male, and 70% Eastern Cooperative Oncology Group performance status 0–1; 32% had oral cavity and 30%
oropharyngeal cancers. The most common first-line regimen across all countries consisted of platinum-based
combinations (73%), including platinum+ 5-fluorouracil (5-FU) (26%), cetuximab + platinum ± 5-FU (22%),
or taxane + platinum ± 5-FU (16%). However, use of different platinum-based combinations varied
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substantially; administration of cetuximab + platinum ± 5-FU was frequent in Italy (81%), Germany (46%)
and Spain (38%), whereas use in other countries was limited. Median follow-up was 22.6 months (95% con-
fidence interval [CI]: 21.5–24.6 months). Median real-world overall survival was only 8.0 months (95% CI:
7.0–8.0), with one-year survival reaching only 30.9% (95% CI: 27.5–34.3).
Conclusion: Systemic therapies used in clinical practice for patients with R/M HNSCC vary substantially across
countries. Prognosis remains poor in this patient population, highlighting the need for newer, more efficacious
treatments.
Introduction
Head and neck cancers encompass a range of tumours arising in the
oral cavity, pharynx, larynx, salivary glands, nasal cavity and paranasal
sinuses [1]. Head and neck squamous cell carcinoma (HNSCC) is the
predominant histological type, which includes cancers of the or-
opharynx, larynx, hypopharynx and lip/oral cavity. HNSCC is the 7th
leading cause of cancer-related mortality: an estimated 705,781 new
cases and 358,144 deaths were attributable to HNSCC globally in 2018
[2]. Whereas newly diagnosed distant metastatic HNSCC (Stage IVc) is
uncommon (3.5% of newly diagnosed HNSCC), 58% of patients with
HNSCC initially present with locoregionally advanced disease (stage
III–IVb) [3,4].
A significant proportion of patients initially diagnosed with locor-
egionally advanced HNSCC develop disease recurrence, in 30% to 45%
within the first year following multi-modal treatment consisting of
surgery and/or chemoradiation [5]. Patients with recurrent and/or
metastatic (R/M) HNSCC present a therapeutic challenge [6,7]. Despite
available chemotherapeutic and targeted therapies, the prognosis of
patients with R/M HNSCC is poor. Historically, first-line treatment of
R/M HNSCC consisted of platinum-based chemotherapy (cisplatin or
carboplatin) in combination with 5-fluorouracil (5-FU) or a taxane
(docetaxel or paclitaxel). These platinum-based combination regimens
resulted in median overall survival (OS) ranging from 5.0 to 8.7 months
across trials [8,9]. Most recent evidence from prospective clinical trial
data reported an improvement in the median OS to 10.1 months for the
targeted systemic therapy cetuximab combined with platinum-based
chemotherapy, and thereby defined a new standard of care in first-line
treatment of R/M HNSCC according to clinical guidelines [6,7,10].
However, in some countries, the use of cetuximab in combination with
platinum-based therapy may be limited due to toxicity concerns or
regulatory and reimbursement restrictions, potentially resulting in dif-
ferent standard treatment patterns across various regional settings
[11,12].
Treatment choice remains heterogeneous for patients whose disease
has progressed following first-line platinum-based therapy. Historically,
evidence remained limited and single-agent chemotherapy or cetux-
imab were considered standards of care [6,7]. Clinical guidelines in
Spain have recently highlighted the clinical benefits of weekly pacli-
taxel plus cetuximab for patients who have progressed on or are in-
tolerant of platinum-based therapy [13]. More recently, studies of
programmed cell death protein 1 (PD-1) inhibitors, nivolumab and
pembrolizumab, reported improved OS after platinum-failure and re-
present preferred choices in guidelines, where available [7].
Given a lack of universally accepted standard-of-care treatment for
patients with R/M HNSCC, there are limited data describing how R/M
HNSCC is treated in clinical practice [14–17]. Furthermore, there is a
paucity of data focused on survival outcomes with current use of sys-
temic therapies for R/M HNSCC outside of the clinical trial setting to
help identify unmet needs in this population.
To this end, the Global Longitudinal Assessment of Treatment
Outcomes in Squamous Cell Carcinoma of the Head and Neck (GLANCE
H&N) chart review study was designed to explore treatment patterns
and OS outcomes in patients with R/M HNSCC who received systemic
therapy.
Methods
Study design and data collection
The GLANCE H&N retrospective observational study was conducted
at 71 sites in nine countries across Europe (Germany, United Kingdom,
Spain, Italy), Asia Pacific (Taiwan, South Korea, Australia), and Latin/
North America (Brazil and Canada) (Fig. 1). The study protocol was
approved by relevant national and local regulatory authorities.
Adult patients with R/M HNSCC who initiated first-line systemic
Fig. 1. Scope of the GLANCE H&N study. UK: United Kingdom.
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therapy for the treatment of R/M HNSCC (defined as the index date)
between the January 1, 2012 and June 30, 2013 eligibility period were
identified (Fig. 2). For sites in Germany, Australia and Canada the
eligibility period was extended to January 1, 2011 through December
31, 2013 to increase patient enrolment. Patients were followed from the
index date through December 31, 2015 to collect data on clinical
characteristics, treatment patterns and survival outcomes. Initial diag-
nosis and treatment information were collected during the background
period prior to the index date.
Anonymized data were gathered by study investigators and site staff
through manual chart review into an electronic case report form (e-
CRF). Additional details on the study design and data collection pro-
cedures are provided in the Supplementary Table 1.
Patient population
Adult patients were eligible for inclusion if they had a histopatho-
logical or cytological diagnosis of HNSCC involving the lip/oral cavity,
oropharynx, hypopharynx or larynx, and initiated first-line systemic
therapy for the treatment of locoregional recurrent HNSCC (including
second primary tumour and primary tumour relapse) with or without
distant metastases, distant metastatic recurrent HNSCC or newly diag-
nosed metastatic HNSCC (stage IVc). Patients could be included if they
participated in a clinical trial at any line of treatment. Patients were
excluded if they had: cutaneous squamous cell carcinoma involving the
lip; cancers involving the nasopharynx, nasal cavity, paranasal sinuses,
salivary glands or thyroid; received locoregional treatment (radiation
or surgery) with curative intent in the context of relapsed/metastatic
disease; and had not received any systemic therapy for the treatment of
R/M HNSCC.
Subgroup analyses were conducted for platinum-progressed R/M
HNSCC patients, defined as patients who had experienced disease
progression after prior treatment with a platinum-containing regimen
for the treatment of R/M HNSCC or in the locoregionally advanced
disease setting. Treatment regimens for the next line of therapy for
patients with platinum progressed R/M HNSCC were defined based on
the setting of prior platinum-based therapy exposure:
(1) For patients who received a platinum-based therapy for the treat-
ment of R/M HNSCC and who had no prior platinum-based therapy
or whose last date of platinum-based therapy in the locally ad-
vanced HNSCC setting occurred > 6 months prior to the index
date, the next line of systemic therapy for R/M HNSCC was re-
ported.
(2) For patients whose last date of platinum-based therapy in the lo-
cally advanced HNSCC setting occurred ≤ 6 months prior to the
index date, the first-line systemic therapy for R/M HNSCC was
defined from the index date.
Study outcomes
Primary endpoints included systemic treatment patterns and treat-
ment duration according to line of therapy among patients with R/M
HNSCC in the overall and platinum-progressed populations. Treatment
duration was defined as the time (in months) between the first and last
administration across all agents within each regimen. Secondary end-
points included OS in the overall and platinum-progressed populations.
OS according to country and according to common treatment regimens
were descriptively presented. OS was defined from the date of first-line
systemic therapy until death from any cause; patients still alive at the
end of follow-up were censored as of December 31, 2015.
Statistical analysis
Descriptive statistics were reported for demographic, clinical and
treatment characteristics. OS analyses were performed using the
Kaplan-Meier (KM) product limit method; no imputation was made for
missing variables. KM curves and median real-world OS (rwOS) were
reported in months, and survival rates at landmark time points (e.g., 6
and 12 months) were reported. Log-rank tests were conducted to
compare rwOS across countries and common treatment regimens.
A multivariate Cox proportional hazard model was constructed to
identify prognostic factors for OS with first-line therapy. Hazard ratios
(HRs) and 95% confidence intervals (95% CIs) were calculated and
reported in Forest plots. The model covariate list included the following
patient characteristics: age, gender, history of smoking, alcohol con-
sumption, comorbidities, tumour location, TNM disease stage at diag-
nosis, disease status at index date, performance status at index date/
Eastern Cooperative Oncology Group (ECOG) criteria, first-line treat-
ment regimens and prior therapies, including radiotherapy, surgery and
systemic therapy.
Analyses were performed using SAS V-9.3 (SAS Institute, Cary, NC,
USA).
Results
Patient demographics
The study population included 733 patients from 71 sites (Table 1;
Fig. 1). Median age was 60 years (inter-quartile range [IQR] 54–67),
84.4% were male, and 76.7% were current/former smokers (Table 1;
Supplementary Table 2). Patient demographics were largely consistent
across countries except for smoking status and alcohol use as risk fac-
tors for HNSCC: a higher proportion of patients were current/former
Fig. 2. Design of the GLANCE H&N study. Investigators in the UK, Italy and Spain (Europe), Taiwan and South Korea (Asia-Pacific) and Brazil (Latin/North America)
enrolled patients diagnosed between January 1, 2012 and December 31, 2013 (eligibility period). For investigators in Germany (Europe), Australia (Asia-Pacific) and
Canada (Latin/North America) this period was extended to January 1, 2011 through December 31, 2013 to increase patient enrolment. HNSCC: head and neck
squamous cell carcinoma; UK: United Kingdom.
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smokers in Spain, Taiwan, Australia, Brazil, and Canada (82.8–87.5%),
and heavy alcohol use was reported in UK, Spain, Taiwan and Australia
(28.8–45.5%) (Supplementary Table 2). Among patients with cancer of
the oropharynx (N = 221), only 25.3% were tested for human
papillomavirus (HPV) infection (N = 56) based on P16 staining, and
15.8% tested positive for HPV infection (N = 35) (Supplementary
Table 2).
Table 1
Demographic and clinical characteristics of patients with R/M HNSCC, overall and by country.
Characteristic Overall
(N = 733)
Europe Asia Pacific Latin/North America
Germany
(N = 102)
UK
(N = 95)
Spain
(N = 88)
Italy
(N = 69)
Taiwan
(N = 111)
South Korea
(N = 76)
Australia
(N = 53)
Brazil
(N = 98)
Canada
(N = 41)
Gender, n (%)
Male 619 (84.4) 90 (88.2) 71 (74.7) 74 (84.1) 58 (84.1) 106 (95.5) 57 (75.0) 46 (86.8) 85 (86.7) 32 (78.0)
Age at Index date
Median (IQR), years 60.0
(54.0–67.0)
61.0
(55.0–68)
60.0
(54.0–67.0)
60.0
(54.0–67.0)
60.0
(54.0–67.0)
60.0
(54.0–67.0)
60.0
(54.0–67.0)
62.0
(55.0–67.0)
59.0
(55.0–66.5)
61.0
(55.0–67.0)
Tumour location, n (%)
Lip/oral cavity 236 (32.2) 14 (13.7) 30 (31.6) 22 (25.0) 24 (34.8) 68 (61.3) 33 (43.4) 11 (20.8) 24 (24.5) 10 (24.4)
Oropharynx 221 (30.2) 33 (32.4) 41 (43.2) 25 (28.4) 12 (17.4) 15 (13.5) 11 (14.5) 25 (47.2) 38 (38.8) 21 (51.2)
Larynx 137 (18.7) 21 (20.6) 16 (16.8) 25 (28.4) 22 (31.9) 2 (1.8) 15 (19.7) 12 (22.6) 18 (18.4) 6 (14.6)
Hypopharynx 98 (13.4) 28 (27.5) 8 (8.4) 11 (12.5) 8 (11.6) 22 (19.8) 10 (13.2) 1 (1.9) 7 (7.1) 3 (7.3)
Othera 41 (5.6) 6 (5.9) 0 (0) 5 (5.7) 3 (4.3) 4 (3.6) 7 (9.2) 4 (7.5) 11 (11.2) 1 (2.4)
Disease status at Index date, n (%)
Recurrent/Progressed 590 (80.5) 79 (77.5) 77 (81.0) 73 (83.0) 57 (82.6) 90 (81.1) 63 (82.9) 44 (83.0) 71 (72.4) 36 (87.8)
Locoregional recurrent disease,
no distant metastases
263 (35.9) 20 (19.6) 44 (46.3) 34 (38.6) 13 (18.8) 59 (53.2) 17 (22.4) 28 (52.8) 41 (41.8) 7 (17.1)
Locoregional recurrent disease,
distant metastases
168 (22.9) 21 (20.6) 17 (17.9) 16 (18.2) 16 (23.2) 25 (22.5) 28 (36.8) 10 (18.9) 16 (16.3) 19 (46.3)
Distant metastatic recurrent
disease
106 (14.5) 30 (29.4) 13 (13.7) 15 (17.0) 10 (14.5) 6 (5.4) 18 (23.7) 4 (7.5) 4 (4.1) 6 (14.6)
Progression of residual local or
distant disease
53 (7.2) 8 (7.8) 3 (3.2) 8 (9.1) 18 (26.1) 0 (0) 0 (0) 2 (3.8) 10 (10.2) 4 (9.8)
Newly diagnosed metastatic
disease (stage IVc)
143 (19.5) 23 (22.5) 18 (19.0) 15 (17.0) 12 (17.4) 21 (18.9) 13 (17.1) 9 (17.0) 27 (27.6) 5 (12.2)
ECOG PS at Index date, n (%)
0–1 515 (70.2) 60 (58.8) 82 (86.3) 64 (72.7) 36 (52.2) 78 (70.3) 61 (80.3) 41 (77.3) 71 (72.4) 22 (53.6)
2 109 (14.9) 29 (28.4) 7 (7.4) 11 (12.5) 3 (4.3) 21 (18.9) 6 (7.9) 9 (17.0) 16 (16.3) 7 (17.1)
3–4 25 (3.4) 8 (7.8) 0 (0) 0 (0) 1 (1.4) 7 (6.3) 1 (1.3) 1 (1.9) 5 (5.1) 2 (5.0)
Unknown 84 (11.4) 5 (4.9) 6 (6.3) 13 (14.8) 29 (42.0) 5 (4.5) 8 (10.5) 2 (3.8) 6 (6.1) 10 (24.4)
Systemic therapy prior to Index date, n (%)
Yes 337 (46.0) 44 (43.1) 39 (41.1) 41 (46.6) 34 (49.3) 57 (51.4) 32 (42.1) 25 (47.2) 44 (44.9) 21 (51.2)
Prior Platinum 304 (90.2) 37 (84.1) 36 (92.3) 35 (85.4) 33 (97.1) 52 (91.2) 31 (96.9) 19 (76.0) 43 (97.7) 18 (85.7)
Platinum ≤ 6 months prior to
Index date
102 (33.6) 10 (27.0) 7 (19.4) 8 (22.9) 9 (27.3) 32 (61.5) 9 (29.0) 6 (31.6) 17 (39.5) 4 (22.2)
Unknown 150 (20.5) 23 (22.5) 18 (18.9) 14 (15.9) 12 (17.4) 25 (22.5) 13 (17.1) 9 (17.0) 30 (30.6) 6 (14.6)
ECOG: Eastern Cooperative Oncology Group; HNSCC: head and neck squamous cell carcinoma; IQR: interquartile range; PS: performance status; R/M: recurrent and/
or metastatic; UK: United Kingdom.
a Includes other and ill-defined sites in lip, oral cavity and pharynx.
Table 2
First-line treatment patterns for patients with R/M HNSCC, overall and by country.
Systemic therapy Overall
(N = 733)
Europe Asia Pacific Latin/North America
Germany
(N = 102)
UK
(N = 95)
Spain
(N = 88)
Italy
(N = 69)
Taiwan
(N = 111)
South Korea
(N = 76)
Australia
(N = 53)
Brazil
(N = 98)
Canada
(N = 41)
Any combination, n (%) 575 (78.4) 86 (84.3) 93 (97.9) 72 (81.8) 67 (97.1) 92 (82.9) 59 (77.6) 34 (64.2) 48 (49.0) 24 (58.5)
Platinum-based combination 535 (73.0) 78 (76.5) 93 (97.9) 51 (58.0) 67 (97.1) 87 (78.4) 59 (77.6) 34 (64.2) 47 (48.0) 19 (46.3)
Platinum + 5-FU 193 (26.3) 4 (3.9) 67 (70.5) 8 (9.1) 1 (1.4) 40 (36.0) 41 (53.9) 24 (45.3) 5 (5.1) 3 (7.3)
Cetuximab + platinum ± 5-FU 159 (21.7) 47 (46.1) 13 (13.7) 33 (37.5) 56 (81.2) 0 (0) 0 (0) 0 (0) 4 (4.1) 6 (14.6)
Taxane + platinum ± 5-FU 119 (16.2) 11 (10.8) 13 (13.7) 10 (11.4) 5 (7.2) 10 (9.0) 17 (22.4) 6 (11.3) 38 (38.8) 9 (22.0)
Cetuximab + platinum + taxane ± 5-FU 18 (2.4) 16 (15.7) 0 (0) 0 (0) 2 (2.9) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Other platinum 46 (6.3) 0 (0) 0 (0) 0 (0) 3 (4.3) 37 (33.3) 1 (1.3) 4 (7.5) 0 (0) 1 (2.4)
Non-platinum combination 40 (5.4) 8 (7.8) 0 (0) 21 (23.9) 0 (0) 5 (4.5) 0 (0) 0 (0) 1 (1.0) 5 (12.2)
Cetuximab + taxane 27 (3.7) 6 (5.9) 0 (0) 20 (22.7) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1.0) 0 (0)
Other non-platinum 13 (1.8) 2 (2.0) 0 (0) 1 (1.1) 0 (0) 5 (4.5) 0 (0) 0 (0) 0 (0) 5 (12.2)
Any monotherapy, n (%) 147 (20.1) 16 (15.7) 2 (2.1) 16 (18.2) 2 (2.9) 19 (17.1) 12 (15.8) 18 (34.0) 46 (47.0) 16 (39.1)
Platinum 52 (7.1) 0 (0) 1 (1.1) 4 (4.5) 0 (0) 14 (12.6) 1 (1.3) 5 (9.4) 23 (23.5) 4 (9.8)
Taxane 36 (4.9) 6 (5.9) 0 (0) 4 (4.5) 1 (1.4) 0 (0) 4 (5.3) 0 (0) 18 (18.4) 3 (7.3)
Methotrexate 28 (3.8) 0 (0) 0 (0) 5 (5.7) 0 (0) 1 (0.9) 0 (0) 11 (20.8) 3 (3.1) 8 (19.5)
Cetuximab 22 (3.0) 10 (9.8) 1 (1.1) 3 (3.4) 0 (0) 1 (0.9) 2 (2.6) 2 (3.8) 2 (2.0) 1 (2.4)
Other 9 (1.2) 0 (0) 0 (0) 0 (0) 1 (1.4) 3 (2.7) 5 (6.6) 0 (0) 0 (0) 0 (0)
Clinical trial, n (%) 11 (1.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 5 (6.6) 1 (1.9) 4 (4.0) 1 (2.4)
5-FU: fluorouracil; HNSCC: head and neck squamous cell carcinoma; R/M: recurrent and/or metastatic; UK: United Kingdom.
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HNSCC clinical characteristics
The most common primary tumour sites were the lip/oral cavity
(32.2%) or the oropharynx (30.2%), although primary tumour location
varied across countries/regions (Table 1). Oropharyngeal cancers were
more common in Latin/North America (51.2% Canada; 38.8% Brazil),
Australia (47.2%) and Northern Europe (43.2% UK; 32.4% Germany).
Oral cavity cancers were more common in the Asia-Pacific region
(61.3% Taiwan; 43.4% South Korea).
The majority of patients had recurrent/progressive disease at the
index date (80.5%), of whom over one-third had distant metastases
(37.4%); 19.5% were newly diagnosed metastatic; no notable differ-
ences were observed across countries (Table 1). Most patients (70.2%)
had good performance status (ECOG 0–1), although a lower proportion
of patients with good performance status were seen in Canada, Ger-
many, and Italy (52.2–58.8%).
Systemic therapy was administered to 46.0% of patients prior to the
index date, among which platinum-based chemotherapy was the most
common (90.2%). Only Australia had a notably lower proportion of
patients with prior platinum-based chemotherapy (76.0%).
Approximately one-third of patients who received platinum-based
therapy received their last dose ≤ 6 months prior to index date.
Treatment patterns in R/M HNSCC
The most common first-line systemic therapy regimens consisted of
platinum-based combinations (73.0%) across all countries, including
platinum + 5-FU (26.3%), cetuximab + platinum ± 5-FU (21.7%), or
taxane + platinum ± 5-FU (16.2%; Table 2). However, use of dif-
ferent platinum-based combinations varied substantially across coun-
tries; administration of cetuximab + platinum ± 5-FU was frequent in
Italy (81.2%), Germany (46.1%), and Spain (37.5%), whereas the use of
cetuximab + platinum ± 5-FU was limited in other countries. Pla-
tinum with 5-FU was the most common first-line regimen in the UK
(70.5%) and in Asia-Pacific countries (36.0–53.9%), whereas
taxane + platinum ± 5-FU was most frequent in Brazil (38.8%) and
Canada (22.0%). Monotherapy was frequently used in the first-line
setting in Brazil (47.0%), Canada (39.1%) and Australia (34.0%), but
accounted for first-line treatment in only 20.1% of patients overall.
Following first-line systemic therapy, 39.4% of patients underwent
second-line therapy (N = 289), with estimates ranging 23.2%–54.5%
across countries (Supplementary Fig. 1). Monotherapy was the most
common second-line treatment overall (54.3%) among which a taxane
(23.5%) or methotrexate (11.8%) were most common (Table 3). Re-
treatment with platinum-based combinations was also common in
certain countries (29.1% overall), particularly in Taiwan (54.3%), UK
(45.4%) and Germany (36.4%), whereas in Italy (82.1%), Brazil
(75.7%) and Australia (75.0%) monotherapy was the predominate ap-
proach. In Spain, cetuximab + taxane combination was more com-
monly used (31.3%) as an alternative to platinum-based combinations
in the second-line setting. Following second-line therapy, very few
patients received third-line (12.7%) and fourth-line therapy (4.1%),
although patient numbers were too small to definitively examine trends
(Supplementary Fig. 1).
Among the full cohort of 733 patients, 380 patients (51.8%) had
progressed on platinum-based therapy and received additional systemic
therapy (Supplementary Table 3). Re-treatment with platinum-based
combinations was common across all countries (46.0%), and 38.4% of
patients received monotherapy, primarily consisting of taxane (17.4%),
methotrexate (6.8%), or cetuximab (5.7%). Utilization of mono-
therapies and re-treatment with platinum-based combinations differed
greatly across countries. Re-treatment with platinum-based combina-
tions was very common in Taiwan (71.2%) and UK (70.6%), and least
common in Spain where cetuximab + taxane combination was more
commonly used (38.8%). Monotherapies were most commonly ad-
ministered in Australia (65.2%) and Brazil (60.4%), and among the
monotherapies administered, taxanes were generally used across most
countries.
Treatment duration in R/M HNSCC
Median treatment duration was 2.0 months (IQR 1.0–4.0 months)
across all first-line systemic therapies administered (Supplementary
Table 4). Median treatment duration was longest for cetux-
imab + platinum ± 5-FU after taking cetuximab maintenance therapy
into account (3.0 months; IQR 2.0–5.0 months) and was similar for
platinum + 5-FU (2.0 months; IQR 1.0–3.9 months) and taxane + pla-
tinum ± 5-FU (2.0 months; IQR 1.0–3.0 months). Median treatment
duration was 2.0 months for patients who received second-line therapy
(IQR 1.0–3.0; Supplementary Table 5).
Median treatment duration for patients who progressed on pla-
tinum-based therapy and received additional systemic therapy was
2.0 months (IQR 1.0–3.9 months) (Supplementary Table 6).
Table 3
Second-line treatment patterns for patients with R/M HNSCC, overall and by country.
Systemic therapy Overall
(N = 289)
Europe Asia Pacific Latin/North America
Germany
(N = 44)
UK
(N = 22)
Spain
(N = 48)
Italy
(N = 28)
Taiwan
(N = 35)
South Korea
(N = 41)
Australia
(N = 20)
Brazil
(N = 37)
Canada
(N = 14)
Any combination, n (%) 116 (40.2) 23 (52.3) 10 (45.4) 25 (52.1) 5 (17.9) 23 (65.7) 10 (24.4) 5(25.0) 9 (24.3) 6 (42.9)
Platinum-based combination 84 (29.1) 16 (36.4) 10 (45.4) 10 (20.8) 1 (3.6) 19 (54.3) 10 (24.4) 5 (25.0) 9 (24.3) 4 (28.6)
Platinum + 5-FU 24 (8.3) 0 (0) 3 (13.6) 5 (10.4) 0 (0) 8 (22.8) 3 (7.3) 3 (15.0) 2 (5.4) 0 (0)
Cetuximab + platinum ± 5-FU 25 (8.6) 13 (29.5) 0 (0) 3 (6.2) 1 (3.6) 1 (2.9) 3 (7.3) 1 (5.0) 1 (2.7) 2 (14.3)
Taxane + platinum ± 5-FU 25 (8.6) 3 (6.8) 5 (22.7) 1 (2.1) 0 (0) 4 (11.4) 4 (9.8) 0 (0) 6 (16.2) 2 (14.3)
Other platinum 10 (3.5) 0 (0) 2 (9.1) 1 (2.1) 0 (0) 6 (17.4) 0 (0) 1 (5.0) 0 (0) 0 (0)
Non-platinum combination 32 (11.1) 7 (15.9) 0 (0) 15 (31.3) 4 (14.3) 4 (11.4) 0 (0) 0 (0) 0 (0) 2 (14.3)
Cetuximab + taxane 23 (8.0) 7 (15.9) 0 (0) 15 (31.3) 1 (3.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Other non-platinum 9 (3.1) 0 (0) 0 (0) 0 (0) 3 (10.7) 4 (11.4) 0 (0) 0 (0) 0 (0) 2 (14.3)
Any monotherapy, n (%) 157 (54.3) 21 (47.7) 8 (36.4) 22 (45.8) 23 (82.1) 12 (34.3) 21 (51.2) 15 (75.0) 28 (75.7) 7 (50.0)
Platinum 17 (5.9) 1 (2.3) 3 (13.6) 3 (6.3) 2 (7.1) 5 (14.3) 0 (0) 0 (0) 2 (5.4) 1 (7.1)
Taxane 68 (23.5) 10 (22.7) 3 (13.6) 7 (14.6) 15 (53.6) 3 (8.6) 14 (34.1) 6 (30.0) 6 (16.2) 4 (28.6)
Methotrexate 34 (11.8) 4 (9.1) 0 (0) 5 (10.4) 0 (0) 2 (5.7) 0 (0) 7 (35.0) 16 (43.2) 0 (0)
Cetuximab 15 (5.2) 2 (4.5) 2 (9.1) 3 (6.3) 0 (0) 0 (0) 5 (12.2) 2 (10.0) 0 (0) 1 (7.1)
Other 23 (8.0) 4 (9.1) 0 (0) 4 (8.3) 6 (21.4) 2 (5.7) 2 (4.9) 0 (0) 4 (10.8) 1 (7.1)
Clinical trial, n (%) 16 (5.5) 0 (0) 4 (18.2) 1 (2.1) 0 (0) 0 (0) 10 (24.4) 0 (0) 0 (0) 1 (7.1)
5-FU: fluorouracil; HNSCC: head and neck squamous cell carcinoma; R/M: recurrent and/or metastatic; UK: United Kingdom.
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Overall survival in R/M HNSCC
Median follow-up duration was 22.6 months (95% CI:
21.5–24.6 months). The median rwOS for R/M HNSCC patients who
initiated first-line systemic therapy was 8.0 months (95% CI: 7.0–8.0),
with one-year survival reaching only 30.9% (95% CI: 27.5–34.3%)
(Table 4). Some variation in median rwOS was observed across coun-
tries, ranging from 6.0 months (95% CI: 4.9–12.0) to 10.5 months (95%
CI: 8.0–14.0), but the confidence intervals consistently overlapped
suggesting no notable country-specific differences. Result of the log-
rank test did suggest a difference in OS across countries (log-rank test
p = 7e-07); however, these results should be interpreted with care
given the low patient numbers in certain countries at later time points.
Median rwOS for the most common first-line platinum-based regimens
were similar: median rwOS was 8.0 months (95% CI: 7.0–9.0) for pla-
tinum + 5-FU, 8.0 months (95% CI: 7.0–10.0) for cetux-
imab + platinum ± 5-FU, and 7.1 months (95% CI: 6.0–9.0) for
taxane plus platinum ± 5-FU (Fig. 3; log-rank test p = 0.2). In the
subgroup of patients who progressed on platinum therapy (n = 361),
median rwOS was 6.0 months (95% CI: 5.0–7.0), and one-year survival
rate reached only 22.3% (95% CI: 18.0%–26.7%; Supplementary
Table 6). Median rwOS for the most common regimens used in the
subgroup of patients who progressed on platinum therapy were similar:
median rwOS was 6.0 months (95% CI: 5.0–7.9) for platinum-based
combinations, 4.0 months (95% CI: 3.0–6.0) for taxane monotherapy,
and 6.0 months (95% CI: 5.0–8.0) for other monotherapies
(Supplementary Fig 2; log- rank test p = 0.1).
Results of the multivariate Cox proportional hazards regression to
identify factors that were prognostic of OS for the overall population
are presented in Supplementary Fig. 3. As expected, a high ECOG
performance status score (2 or 3–4) was an independent predictor of
worse survival outcomes (ECOG 2: HR 1.42, 95% CI: 1.12–1.8; ECOG
3–4: HR 4.6, 95% CI: 2.99–7.08). There was no significant influence of
type of platinum-based first-line treatment regimen on OS, confirming
the trends observed in the unadjusted KM OS curves. Additional patient
demographic characteristics did not appear to be prognostic of OS. In
addition, no notable differences in OS were observed according to
disease stage at diagnosis and disease status at the index date.
Discussion
The GLANCE H&N was a multisite, retrospective observational
study that examined the treatment patterns and outcomes of patients
with R/M HNSCC in oncology practices across nine regionally re-
presentative countries in Europe, Asia Pacific and Latin/North America.
Consistent with prior studies and trials in R/M HNSCC [14,18], the
study population was predominately male (84%), with median age of
60 years and a higher proportion of patients with good performance
status (70% ECOG 0–1), confirming the generalizability of the study
population. Only 25% of patients with cancer of the oropharynx were
tested for HPV infection, which may not be surprising as the study
eligibility period (2011–2013) largely predates the recent awareness of
HPV infection as a major risk factor for HNSCC [19].
Overall, the results of the study identified that platinum-based
combination regimens were most widely used as first-line therapy
(73%), and monotherapies were most frequently used in the second-line
setting (54%). However, the use of systemic therapies for patients with
R/M HNSCC varied substantially across countries. Among platinum-
based combinations utilized in the first-line setting, administration of
cetuximab in combination with platinum-based therapy was frequent in
Italy, Germany and Spain, but was seldom used in other countries de-
spite regulatory approval of this regimen in most countries (excluding
Canada), and consistent designation as preferred treatment option by
global clinical guidelines (EXTREME regimen: cetux-
imab + platinum + 5-FU) [6,7,20]. Potential reasons for low utiliza-
tion of cetuximab in combination with platinum-based therapy may be
due to toxicity concerns or regulatory and reimbursement restrictions
[11,12].
Treatment patterns in the UK and Germany are largely consistent
with prior publications, which have identified predominate use of
platinum in combination with 5-FU in the UK and cetuximab in com-
bination with platinum in Germany [14,15]. Among Asia-Pacific
countries in this study, taxanes in combination with platinum were
most frequent. A study from the United States similarly highlighted
higher use of taxanes and platinum combination and infrequent use of
cetuximab and platinum combinations [16]. Among studies examining
second-line treatment patterns, results also confirm predominate use of
taxanes and methotrexate monotherapies as seen in this study [14]. As
an exception, use of cetuximab in combination with a taxane was
common in Spain, as currently recommended by local clinical guide-
lines [13].
Median rwOS with first-line therapy in the study population was
only 8.0 months, with one-year survival reaching only 30.9%. Despite
differences in treatment patterns, OS was similar across countries and
Table 4
Overall survivala for patients who initiated first-line systemic therapy for R/M HNSCC, overall and by country.
Overall Survival Overall
(N = 722)
Europe Asia Pacific Latin/North America
Germany
(N = 102)
UK
(N = 95)
Spain
(N = 88)
Italy
(N = 69)
Taiwan
(N = 111)
South Korea
(N = 71)
Australia
(N = 52)
Brazil
(N = 94)
Canada
(N = 40)
Median (95% CI)b 8.0 (7.0–8.0) 7.0 (6.0–8.0) 7.0 (5.0–8.0) 10.5
(8.0–14.0)
7.0 (6.0–8.0) 9.0
(6.0–11.0)
9.0
(7.9–11.0)
7.0
(6.0–12.0)
10.0
(8.0–13.0)
6.0 (4.9–12.0)
Rate, % (95% CI)b
6 months n 441 60 50 60 40 65 48 33 63 22
61.1
(57.5–64.7)
58.8
(49.2–68.4)
52.6
(42.6–62.6)
68.2
(58.5–77.9)
58.0
(46.3–69.7)
58.6
(49.4–67.8)
67.6
(56.7–78.5)
63.5
(50.4–76.6)
67.0
(57.5–76.5)
55.0 (39.6–70.4)
12 months n 223 28 16 37 14 43 19 17 38 11
30.9
(27.5–34.3)
27.5
(18.8–36.2)
16.8
(9.3–24.3)
42.0
(31.7–52.3)
20.3
(10.8–29.8)
38.7
(29.6–47.8)
26.8
(16.5–37.1)
32.7
(20.0–45.4)
40.4
(30.5–50.3)
27.5 (13.7–41.3)
2 years n 104 8 2 21 3 26 9 9 20 6
14.4
(11.8–17.0)
7.8
(2.6–13.0)
2.1 (0.0–5.0) 23.9
(15.0–32.8)
4.3 (0.0–9.1) 23.4
(15.5–31.3)
12.7
(4.9–20.5)
17.3
(7.0–27.6)
21.3
(13.0–29.6)
15.0 (3.9–26.1)
3 years n 49 2 0 9 1 17 3 4 11 2
6.8 (5.0–8.6) 2.0 (0.0–4.8) 0 (NA) 10.2
(3.9–16.5)
1.4 (0.0–4.2) 15.3
(8.6–22.0)
4.2 (0.0–8.2) 7.7
(0.4–15.0)
11.7
(5.2–18.2)
5.0 (0.0–11.0)
95% CI: confidence interval; HNSCC: head and neck squamous cell carcinoma; NA: not applicable; R/M: recurrent and/or metastatic; UK: United Kingdom.
a Overall survival analyses exclude patients who participated in clinical trials.
b log rank test p = 7e-07.
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among the main systemic therapies administered. As expected, a high
ECOG performance status score (2 or 3–4) was an independent pre-
dictor of worse survival outcomes; otherwise, no notable differences in
OS were observed according to patient demographics or disease char-
acteristics such as recurrent versus distant metastatic disease status.
These OS results are largely consistent with previous analyses from
clinical trials and observational studies and underscore the medical
need for novel therapies in R/M HNSCC [14]. Currently, there is a lack
of head-to-head clinical trial comparisons of OS across commonly used
platinum-based regimens, but trial results have indicated median OS
ranging from 10.1 to 11.6 months with cetuximab and platinum com-
binations [10,18] as compared with median OS ranging from 6.8 to
8.1 months with taxane and platinum combinations [8,9,21,22].
Overall, the results of this study highlight that patients with R/M
HNSCC had poor prognosis with use of available therapies during the
study period. More recent trials of immune-oncology (I-O) therapies in
R/M HNSCC patients who have progressed after platinum-based
therapy have demonstrated clinically meaningful improvements in OS.
In the CheckMate 141 trial, nivolumab demonstrated a 32% reduction
in risk of death compared with investigator’s choice therapy (HR: 0.68,
95% CI: 0.54– 0.86) [23]. In the KEYNOTE-40 trial, pembrolizumab
was associated with a 20% reduction in risk of death over investigator’s
choice chemotherapy in patients with R/M HNSCC with disease pro-
gression on or after platinum-containing chemotherapy (HR: 0.80, 95%
CI: 0.65–0.98) [24].
In the first-line R/M HNSCC setting, the Phase 3 KEYNOTE-048 trial
demonstrated that pembrolizumab in combination with chemotherapy
and as monotherapy in patients with programmed death-ligand 1 (PD-
L1) biomarker expression significantly improved OS compared to
standard treatment with cetuximab in combination with platinum-
based chemotherapy. At the second interim analysis, pembrolizumab
monotherapy improved OS versus standard treatment in patients whose
tumours expressed PD-L1 with Combined Positive Score (CPS) ≥ 20
(HR: 0.61, 95% CI: 0.45–0.83) and in patients with CPS ≥ 1 (HR: 0.78,
95% CI: 0.64–0.96) [25]. Pembrolizumab in combination with che-
motherapy improved OS versus standard treatment (HR: 0.77, 95% CI:
0.63–0.93) at the second interim analysis and in the CPS ≥ 20 popu-
lation (HR: 0.60, 95% CI: 0.45–0.82) and CPS ≥ 1 population (HR:
0.65, 95% CI: 0.53–0.80) at the final analysis. Additional phase III trials
of I-O therapies for the first-line treatment of R/M HNSCC are on-going,
including the CheckMate 651 trial of nivolumab in combination with
ipilimumab (NCT02741570) [26], and the KESTREL trial of durva-
lumab monotherapy and in combination with tremelimumab
(NCT02551159) [27].
Limitations of this study include the retrospective nature of this
chart review and potential for documentation bias if there were errors/
omissions in patient medical records. However, these limitations should
be balanced against the study’s strengths, including the large sample of
participating sites and representation from multiple countries.
Nevertheless, the predominance of larger oncology practices that par-
ticipated in this study may limit generalizability of the study findings
with smaller clinical practices within each country. In addition, results
among the countries participating in this study may not be re-
presentative of regional treatment practice among countries not in-
cluded in this study. The study period predates the introduction of I-O
therapies and the recent awareness of HPV infection as a major risk
Fig. 3. Kaplan–Meier curves of overall survival for patients who initiated first-line systemic therapy for R/M HNSCC, overall and by most common regimens. Overall
difference between groups: Log-rank test p = 0.2. Overall survival analyses excluded patients who participated in clinical trials. 5-FU: fluorouracil; 95% CI: 95%
confidence interval; excl: excluding; OS: overall survival; R/M HNSCC: recurrent and/or metastatic head and neck squamous cell carcinoma.
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factor for HNSCC. Future research should explore real-world treatment
patterns after the introduction of I-O therapies, as well as prognostic
factors of survival outcomes such as ECOG performance status, HPV
status, and PD-L1 status, in patients with R/M HNSCC. As new ther-
apeutic advancements emerge, the results of this study will continue to
provide valuable historical benchmark information to inform the evo-
lution of survival outcomes of patients with R/M HNSCC treated with
systemic therapies in clinical practice.
Conclusions
Choice of systemic therapies for patients with R/M HNSCC varies
substantially across countries in routine clinical practice. Prognosis
remains poor with limited therapeutic options, underscoring the need
for newer, more efficacious treatments. Despite differences in treatment
patterns, OS is similar across countries and among main systemic
therapies administered. Future research should explore the evolution of
treatment patterns and survival outcomes in real-world practice after
the recent clinical development of I-O therapies for the treatment of R/
M HNSCC.
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